Article Complete
AIM
Astrazeneca, Qure.ai Complete 5 million AI-enabled chest X-ray Scans
Astrazeneca, Qure.ai Complete 5 million AI-enabled chest X-ray Scans
Scan-dalous Findings

Astrazeneca, Qure.ai Complete 5 million AI-enabled chest X-ray Scans

The screenings identified nearly 50,000 individuals with lung nodules considered high risk for cancer, leading to their referral for further testing and possible diagnosis. 

Published Updated

Key takeaways

  • AstraZeneca and Qure.ai completed 5 million AI-enabled chest X-rays across 20 countries.
  • Screenings identified 50,000 individuals at high risk for lung cancer, prompting further testing.
  • AI technology enhances early lung cancer detection in resource-limited settings.
  • Initiative supports the EDISON Alliance’s goal to improve digital healthcare access by 2030.
  • AI-enabled chest X-rays optimize medical resource use in low- and middle-income countries.
5 min

AstraZeneca and health-tech firm Qure.ai completed 5 million AI-enabled chest X-rays (CXRs) in more than 20 countries in Asia, the Middle East, Africa, and Latin America on Friday.

This can significantly improve early lung cancer risk assessment in resource-limited settings.

The screenings identified nearly 50,000 individuals with lung nodules considered high risk for cancer, leading to their referral for further testing and possible diagnosis, the company said.  

The initiative supports the EDISON Alliance’s 1 Billion Lives Challenge, aiming to deliver digital access to healthcare, education, and financial services to a billion people by 2030.


“Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection,” Ti Hwei How, vice president, International Oncology, AstraZeneca, said in a statement.

The deployment of Qure.ai’s qXR technology, initiated in 2020 under AstraZeneca’s A.Catalyst Network, has been crucial to this success. The AI system helps analyse routine chest X-rays and triage patients for further diagnostic steps such as low-dose CT scans. It has already been successfully implemented in India, Colombia, and El Salvador.

“Five million scans globally is a significant achievement, demonstrating the scalability and effectiveness of AI in improving lung cancer screening in resource-limited settings,” Prashant Warier, CEO and Founder, Qure.ai said.

AI-powered CXRs not only offer early detection but also optimise the use of scarce medical resources. This is particularly critical in low- and middle-income countries (LMICs), where lung cancer mortality rates are rising, unlike in high-income countries where they are declining.”

Data presented at the European Lung Cancer Congress (ELCC) 2025 reinforces the utility of qXR, showing its effectiveness in detecting high-risk lung nodules 54.1% of the time, with supporting data on its cost-effectiveness when applied in countries like Vietnam.

Membership

Stay ahead with AI insights.

Unlimited access to premium articles, exclusive analysis, and the stories shaping India's AI economy.

Subscribe now

AIM Americas

1190 Miraloma Way Suite P, Sunnyvale, CA 94085

AIM India

1st Floor, Sakti Statesman, Bellandur, Bengaluru – 560103

© 2026 AIM. All rights reserved.